Narlumosbart
Bone Diseases
RenJi HospitalPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Bone Diseases cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
VITAMIN D Mark Pegram | Phase 3 | BB |
Calcium | Phase 3 | B |
Denosumab RenJi Hospital | Phase 3 | B |
Apple Cider Vinegar Western University | Early Phase 1 | C |
Same molecule, other indications
Narlumosbart is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →